US Dollar vs MXN

Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.

Regístrate

ENTX

Entera Bio (ENTX)

Entera Bio Ltd

Fecha:

Regulatory News

Text Search:

Ordernar por:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:ENTX

1 2 3 4 5 Próxima >

Fecha	Hora	Fuente	Título	Símbolo	Compañía
15/05/2024	07:00	GlobeNewswire Inc.	Entera Bio Appoints Dr. Rachel B Wagman as Key Clinical Advisor and Scientific Advisory Board Member	NASDAQ:ENTX	Entera Bio Ltd
13/05/2024	06:00	GlobeNewswire Inc.	Entera Bio to Present Phase 1 Data from First-in-Class, PTH(1-34) Peptide Tablets (EB612) for the Treatment of Hypoparathyroidism at ENDO 2024	NASDAQ:ENTX	Entera Bio Ltd
10/05/2024	15:14	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:ENTX	Entera Bio Ltd
10/05/2024	15:10	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ENTX	Entera Bio Ltd
10/05/2024	15:10	GlobeNewswire Inc.	Entera Bio Reports Q1 2024 Financial Results and Provides Business Updates	NASDAQ:ENTX	Entera Bio Ltd
08/04/2024	07:30	GlobeNewswire Inc.	Entera Bio Announces Publication of Oral PTH(1-34) Peptide Tablets (EB613) Phase 2 Trial Data in the Journal of Bone and Mineral Research	NASDAQ:ENTX	Entera Bio Ltd
26/03/2024	07:30	GlobeNewswire Inc.	Entera Bio Announces Key Regulatory Milestone for Oral PTH(1-34) Peptide (EB613) Phase 3 Program: FDA Ruling on Qualifying BMD as a Surrogate Endpoint for Osteoporosis Drugs is Expected Within 10 Months	NASDAQ:ENTX	Entera Bio Ltd
20/03/2024	07:00	GlobeNewswire Inc.	Entera Bio Announces Robust Pharmacokinetic Data for First-in-Class Oral GLP-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome	NASDAQ:ENTX	Entera Bio Ltd
08/03/2024	15:25	Edgar (US Regulatory)	Form S-8 - Securities to be offered to employees in employee benefit plans	NASDAQ:ENTX	Entera Bio Ltd
08/03/2024	15:12	Edgar (US Regulatory)	Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]	NASDAQ:ENTX	Entera Bio Ltd
08/03/2024	15:05	GlobeNewswire Inc.	Entera Bio Announces Full Year 2023 Financial Results and Provides Business Updates	NASDAQ:ENTX	Entera Bio Ltd
04/03/2024	07:30	GlobeNewswire Inc.	Entera Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement	NASDAQ:ENTX	Entera Bio Ltd
15/02/2024	16:10	Edgar (US Regulatory)	Form 424B3 - Prospectus [Rule 424(b)(3)]	NASDAQ:ENTX	Entera Bio Ltd
14/02/2024	23:15	Edgar (US Regulatory)	Form EFFECT - Notice of Effectiveness	NASDAQ:ENTX	Entera Bio Ltd
14/02/2024	05:05	Edgar (US Regulatory)	Form S-3/A - Registration statement under Securities Act of 1933: [Amend]	NASDAQ:ENTX	Entera Bio Ltd
02/02/2024	15:17	Edgar (US Regulatory)	Form S-3 - Registration statement under Securities Act of 1933	NASDAQ:ENTX	Entera Bio Ltd
30/01/2024	07:30	GlobeNewswire Inc.	Entera Bio to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference	NASDAQ:ENTX	Entera Bio Ltd
16/01/2024	07:00	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ENTX	Entera Bio Ltd
02/01/2024	16:19	Edgar (US Regulatory)	Form D - Notice of Exempt Offering of Securities	NASDAQ:ENTX	Entera Bio Ltd
26/12/2023	07:00	GlobeNewswire Inc.	Entera Bio Announces Closing of Private Placement - Extends Cash Runway into 2025	NASDAQ:ENTX	Entera Bio Ltd
29/11/2023	07:30	GlobeNewswire Inc.	Interim Results from Ongoing Clinical Study Confirm EB613 Optimized Profile for Osteoporosis Treatment and Potential for Entera’s Next Generation Oral Peptide Platform	NASDAQ:ENTX	Entera Bio Ltd
14/11/2023	06:30	GlobeNewswire Inc.	Entera Bio Reports Q3 2023 Financial Results, Highlights Transformational Steps and Unveils Vision as Premier Oral Peptide Company with Five Potential Programs in Development	NASDAQ:ENTX	Entera Bio Ltd
09/11/2023	13:30	GlobeNewswire Inc.	Entera Bio Reports Key Milestone Relating to Oral PTH (1-34) Peptide (EB613) Phase 3 Program: ASBMR-SABRE Has Submitted to FDA the Full Qualification Plan to Approve BMD as a Surrogate Endpoint for Osteoporosis	NASDAQ:ENTX	Entera Bio Ltd
16/10/2023	07:00	GlobeNewswire Inc.	Entera Bio Reports Rapid Pharmacodynamic (PD) Response and Consistent Pharmacokinetic (PK) Data for its First-in-Class Oral PTH(1-34) Mini Tablets at the ASBMR 2023 Annual Meeting	NASDAQ:ENTX	Entera Bio Ltd
12/09/2023	07:30	GlobeNewswire Inc.	Entera Bio Announces Collaboration with OPKO Biologics to Develop Oral Peptide Tablet Formulations for Obesity and Intestinal Malabsorption Syndromes	NASDAQ:ENTX	Entera Bio Ltd
05/09/2023	07:00	GlobeNewswire Inc.	Entera Bio to Participate in Upcoming Investor Conferences	NASDAQ:ENTX	Entera Bio Ltd
24/08/2023	07:11	Edgar (US Regulatory)	Form 3 - Initial statement of beneficial ownership of securities	NASDAQ:ENTX	Entera Bio Ltd
16/08/2023	07:30	GlobeNewswire Inc.	Entera Bio to Present Two Abstracts on its First-in-Class, Once Daily Oral hPTH(1-34) Peptide Tablets (EB613) for the Treatment of Post-Menopausal Women at High Risk of Fracture at the American Society for Bone and Mineral Research (ASBMR) Annual Meeting	NASDAQ:ENTX	Entera Bio Ltd
15/08/2023	15:10	Edgar (US Regulatory)	Form DEF 14A - Other definitive proxy statements	NASDAQ:ENTX	Entera Bio Ltd
11/08/2023	15:05	GlobeNewswire Inc.	Entera Bio Announces Q2 2023 Financial Results and Corporate Updates	NASDAQ:ENTX	Entera Bio Ltd

Showing the most relevant articles for your search:NASDAQ:ENTX

1 2 3 4 5 Próxima >

Strategy Shares Newfound...

Barclays Bank Plc Issuer...

Modern Technology (CE)

Meyer Burger Technology (PK)

Vanguard Australian Prop...

Strathcona Resources

RSE Collection (GM)

Delayed Upgrade Clock

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones